Payment overview · 2025
General Payments
$300.48
15 reported records · 8 companies
Healthcare provider profile · identity verified
Robert S Yuhas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOLANA BEACH, CA · NPI 1700897642
Verified facts
What the public records show
CMS Open Payments records show Robert S Yuhas, MD received $300.48 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.65 | 23.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.75 | 22.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.64 | 19.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.40 | 9.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.25 | 7.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.71 | 6.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.86 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.22 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $300.48 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.64 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.99 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 474 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 73 |
| Valsartan | Valsartan | 236 | 46 |
| Gabapentin | Gabapentin | 219 | 39 |
| Eliquis | Apixaban | 217 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 33 |
| Furosemide | Furosemide | 150 | 24 |
| Losartan Potassium | Losartan Potassium | 137 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 24 |
| Metformin Hcl | Metformin Hcl | 115 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 22 |
| Lisinopril | Lisinopril | 99 | 19 |
| Simvastatin | Simvastatin | 87 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 12 |
| Mirtazapine | Mirtazapine | 86 | 12 |
| Finasteride | Finasteride | 80 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 12 |
| Trazodone Hcl | Trazodone Hcl | 72 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 22 |
| Levetiracetam | Levetiracetam | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | suppressed |
| Lactulose | Lactulose | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 12 |
| Potassium Chloride | Potassium Chloride | 59 | suppressed |
| Lorazepam | Lorazepam | 55 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 14 |
| Carvedilol | Carvedilol | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 12 |
| Azithromycin | Azithromycin | 49 | 36 |
| Alprazolam | Alprazolam | 46 | 15 |
| Famotidine | Famotidine | 44 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 43 | suppressed |
| Prednisone | Prednisone | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Omeprazole | Omeprazole | 33 | suppressed |
| Temazepam | Temazepam | 33 | 11 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Cephalexin | Cephalexin | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 12 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Lumigan | Bimatoprost | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Primidone | Primidone | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 13 |
| Dotti | Estradiol | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Roweepra | Levetiracetam | 13 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $300.48 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, EVENITY, FARXIGA, KISUNLA, LEQVIO, OTEZLA, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error